Stock Insider Trading (from SEC Form 4)

CYTX / Cytori Therapeutics, Inc. insiders include HAWRAN PAUL W (), HAYDEN JEREMY B. (General Counsel & VP of BD), Naughton Gail K (), Thompson Tommy G (), and KESTEN STEVEN (Exec VP and Chief MO), HEDRICK MARC H (President and CEO), RICKEY DAVID (), Lim Kian Thiam, Hawkins Richard J () Girao Tiago (VP & Chief Financial Officer), HARRIS JOHN DAVID (VP and GM Cell Therapy), Swissquote Bank SA, LYONS GARY A (), PostFinance AG, .

Cytori Therapeutics, Inc. insider trades are found here. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

Job titles are listed as of the filing and may not be current. Click the link icon to see the full transaction history.

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.
Latest
File Date
Latest
Tran Date
Insider Code Shares Post Shares Percent
Change
Share
Price
Tran Value Post Value Percent
Change
2018-02-15 2018-02-14 PostFinance AG 10% Owner
S -473,831 4,543,086 -9.44 0.3398 -161,008 1,543,741 -10.43
2018-01-11 2018-01-11 Swissquote Bank SA 10% Owner
S -20,000 5,328,229 -0.37 0.34 -6,800 1,811,598 -0.38
2016-08-11 2016-08-10 HARRIS JOHN DAVID VP and GM Cell Therapy
P 2,500 7,000 55.56 2.03 5,075 14,210 35.71
2016-06-16 2016-06-15 LYONS GARY A Director
X 1,900 4,358 77.30
2016-06-15 2016-06-15 KESTEN STEVEN Exec VP and Chief MO
X 200 3,881 5.43
2016-06-15 2016-06-15 HAYDEN JEREMY B. General Counsel & VP of BD
X 1,896 3,643 108.53
2016-06-15 2016-06-15 Girao Tiago VP & Chief Financial Officer
X 5,667 14,084 67.33
2016-06-15 2016-06-15 Hawkins Richard J Director
X 3,356 8,435 66.08
2016-06-15 2016-06-14 Naughton Gail K Director
P 1,000 2,400 71.43 2.10 2,100 5,040 41.67
2016-06-15 2016-06-15 HEDRICK MARC H President and CEO, Director
X 41,305 83,133 98.75
2016-06-15 2016-06-15 RICKEY DAVID Director
X 16,000 71,226 28.97
2015-09-08 2015-09-03 Thompson Tommy G Director
P 25,449 83,600 43.76 0.3745 9,531 31,308 30.44
2015-05-18 2015-05-08 HAWRAN PAUL W Director
A 19,424 123,546 18.66
2015-04-20 2015-04-06 Lim Kian Thiam 10% Owner
S -600,000 7,400,000 -7.50 1.3709 -822,540 10,144,660 -8.11
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related News Stories

BRIEF-Cytori Therapeutics Says David Rickey And Gail Naughton Submitted Resignations As Members Of Board

2018-01-29 reuters
* CYTORI THERAPEUTICS - ON JAN 25, AS PART OF ONGOING RESTRUCTURING DAVID M. RICKEY AND GAIL K. NAUGHTON, SUBMITTED RESIGNATIONS AS MEMBERS OF BOARD (25-2)

Cytori Therapeutics' (CYTX) CEO Marc Hedrick on Q3 2017 Results - Earnings Call Transcript

2017-11-10 seekingalpha
Good afternoon, ladies and gentlemen. Welcome to the Cytori Therapeutics Third Quarter 2017 Earnings Results Call. [Operator Instructions]. (25-2)